Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 7, 2006. The report announces administrative changes to the company's Board of Directors and its committees, effective January 1, 2007.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a corporate governance announcement and does not contain financial performance data.
Material Changes
The primary material change reported is the appointment of new members to Board committees effective January 1, 2007:
- Sir Christopher Gent has been appointed to the Remuneration Committee.
- Dr. Dan Podolsky has been appointed to the Audit Committee.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on operations, risks, contingencies, or unusual items. The document is strictly limited to the disclosure of board committee membership changes.
Investor Verification Checklist
- Verify the effective date of the new committee appointments (January 1, 2007).
- Confirm the full composition of the Audit and Remuneration committees as listed in the filing.
- Note that this filing does not replace or update financial results; refer to the most recent Form 20-F or quarterly reports for financial data.